Francesco Gelsomino (Marcello Tiseo, M Tiseo)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 25

Top Topics

Tyrosine Kinase

Clinical Evaluation

Top Venues

Therapeutic advances in medical oncology

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Anne S Tsao, Melissa Lynne Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael D Offin, Mariano Provencio Pulla, Jeffrey Clarke, Maen Hussain, Gregory A Otterson, Ibiayi Dagogo-Jack, Jonathan Wade Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E Johnson
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Emanuel Raschi, Francesca Comito, Francesco Massari, Francesco Gelsomino
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy 15 (2) (2023)
Alessandro Leonetti, M Verzè, Roberta Minari, F Perrone, L Gnetti, P Bordi, M Pluchino, R Nizzoli, C Azzoni, L Bottarelli, C A M Lagrasta, G Mazzaschi, S Buti, D Gasparro, A Cosenza, L Ferri, M Majori, M De Filippo, L Ampollini, S La Monica, R Alfieri, E M Silini, Francesco Gelsomino
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies. British journal of cancer (2023)
Mirta Mosca, Nicole Conci, Alessandro Di Federico, Valentina Tateo, Valentina Favorito, Arianna Zappi, Francesco Gelsomino, Andrea De Giglio
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. JCO precision oncology 7 (2023)
Emanuel Raschi, Francesca Comito, Francesco Massari, Francesco Gelsomino
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy (2023)
Emanuel Raschi, Francesca Comito, Francesco Massari, Francesco Gelsomino
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy 15 (2) (2023)
Laura Fabbri, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino, Andrea De Giglio
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics (Basel, Switzerland) 14 (1) (2023)
Laura Fabbri, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino, Andrea De Giglio
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics (Basel, Switzerland) 14 (1) (2023)
Emanuel Raschi, Francesca Comito, Francesco Massari, Francesco Gelsomino
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy 15 (2) (2023)
Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. Cancers 14 (23) (2022)
Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. Cancers 14 (23) (2022)
Simone Rossi, Ilaria Cani, Emanuel Raschi, Francesca Comito, Rita Rinaldi, Andrea Ardizzoni, Maria Guarino, Francesco Gelsomino
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Andrea De Giglio, Marta Aprile, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Andrea Ardizzoni
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC). International journal of molecular sciences 23 (18) (2022)
Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. Cancers 14 (23) (2022)
Filippo Gustavo Dall'Olio, Claudia Parisi, Laura Marcolin, Stefano Brocchi, Caroline Caramella, Nicole Conci, Giulia Carpani, Francesco Gelsomino, Stefano Ardizzoni, Paola Valeria Marchese, Alexandro Paccapelo, Giada Grilli, Rita Golfieri, Benjamin Besse, Andrea Ardizzoni
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC. Therapeutic advances in medical oncology 14 (2022)
Elisa Andrini, Alessandro Di Federico, Monia Sisi, Matteo Rosellini, Arianna Palladini, Giuseppe Lamberti, Andrea De Giglio, Francesco Gelsomino
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. Immunotherapy 14 (16) (2022)
Alessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, Dario de Biase, Francesca Giunchi, Arianna Palladini, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. Cancers 14 (14) (2022)
Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. Cancers 14 (23) (2022)
Claudia Parisi, Giuseppe Lamberti, Maurizio Zompatori, Francesco Gelsomino, Stefania Salvagni, Francesca Sperandi, Andrea Ardizzoni
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer. Journal for immunotherapy of cancer 8 (2) (2021)
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, Laura Scalambra, Francesco Gelsomino, Andrea Ardizzoni, Patrizia Nanni, Pier-Luigi Lollini, Arianna Palladini
IFN-γ and CD38 in Hyperprogressive Cancer Development. Cancers 13 (2) (2021)
Francesco Gelsomino, Alessandro Di Federico, Maria Lucia Tardio, Giada Grilli, Antonietta D'Errico, Andrea Ardizzoni, Stefania Salvagni
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report. Investigational new drugs (2021)
Francesco Gelsomino, Francesco Gelsomino, Fausto Barbieri, Ferdinando Riccardi, Luigi Cavanna, Antonio Frassoldati, Angelo Delmonte, Lucia Longo, Claudio Dazzi, Saverio Cinieri, Ida Colantonio, Francesca Sperandi, Giuseppe Lamberti, Stefano Brocchi, Lorenzo Tofani, Luca Boni, Andrea Ardizzoni
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). British journal of cancer 123 (1) (2020)
Giuseppe Lamberti, Francesco Gelsomino, Stefano Brocchi, Antonio Poerio, Barbara Melotti, Francesca Sperandi, Mauro Gargiulo, Claudio Borghi, Michelangelo Fiorentino, Andrea Ardizzoni
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. Therapeutic advances in medical oncology 12 (2020)
Francesco Gelsomino, Giuseppe Lamberti, Marcello Tiseo, Danilo Rocco, Giulia Pasello, Fabiana Letizia Cecere, Antonio Chella, Giada Grilli, Marcella Mandruzzato, Michele Tognetto, Marina Chiara Garassino, Marianna Macerelli, Silvia Novello, Fausto Roila, Ida Colantonio, Francesco Grossi, Michelangelo Fiorentino, Andrea Ardizzoni
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial). Therapeutic advances in medical oncology 12 (2020)
Alessandro Leonetti, Sugandhi Sharma, Roberta Minari, Paola Perego, Elisa Giovannetti, Francesco Gelsomino
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. British journal of cancer 121 (9) (2019)